INTRODUCTION
This article reviews the pathophysiology, diagnosis, evaluation, and management of small fiber neuropathies. In addition, a number of articles within this issue of discuss disorders that cause or overlap with small fiber neuropathy and provide additional information. Scientific advances in small fiber neuropathy that have occurred over the past few years are highlighted in this article.
Small fiber neuropathy refers to disorders that selectively damage the unmyelinated and thinly myelinated sensory and autonomic nerve fibers. Although small fiber neuropathy is often considered synonymous with painful neuropathies that damage nociceptive C-fibers, a larger spectrum of disorders exist. Painless loss of nociceptive C-fibers and damage to peripheral autonomic nerve fibers may also occur and broaden the spectrum of disorders that are considered under the umbrella of small fiber neuropathies. 1 Small fiber neuropathies include a group of disorders that predominantly affect peripheral fibers of the small somatic and autonomic variety. Many disorders, such as diabetes mellitus, may damage both large and small subsets of nerve fibers, so they are not usually considered a true small fiber neuropathy, although they frequently have small nerve fiber involvement. However, there are specific scenarios where small nerve fibers will be selectively damaged, even in diabetes mellitus, and these are discussed in more detail.
HISTORY, EXAMINATION, NEUROPHYSIOLOGY, AND PATHOLOGY History and Examination
Most, but not all, disorders that cause small fiber neuropathy will cause a lengthdependent loss of small nerve fibers, creating the familiar stocking-glove involvement as the disease progresses. 1, 2 Damage and loss of small nerve fibers in the distal extremities will result in a decrease in function in the affected area. This may be reported as loss of thermal or pain sensation. Patients may report some numbness, painless injuries, or inability to sense cold objects or hot water. Damage to distal autonomic nerve fibers may result in loss of sudomotor (sweating) function in the affected regions. 3 Counterintuitively, patients may report hyperhidrosis (increased sweating) in more central regions because of compensatory sweat production to maintain thermoregulatory capacity. Loss of distal autonomic vasomotor control may result in color changes to the skin or loss of distal thermoregulation. The skin over the affected region may appear dry, shiny, atrophic, or discolored. Greater involvement of autonomic nerves in a length-dependent fashion can result in erectile dysfunction, resting tachycardia, gastroparesis, constipation, or urinary retention. 4 Some small fiber neuropathies may present in a nonYlength-dependent fashion. 2 Symptoms of somatic sensory loss will occur in the affected region. Loss of autonomic nerve fibers in a nonYlengthdependent fashion may result in more dramatic changes to autonomic function, resulting in symptoms of orthostatic intolerance, dry mouth, dry eyes, gastroparesis, constipation, or urinary symptoms.
Pain is seen in many, but not all, small fiber neuropathies. A review of painful symptoms and systemic manifestations seen in various conditions associated with small fiber neuropathies is provided in 
Acute intermittent porphyria
Abdominal pain, vomiting, constipation, tachycardia, and muscle weakness are the most frequent presentation, and typically occur during an acute episode.
Patchy paresthesia is common, but pain is not always present.
Chronic alcohol abuse Tremulousness, rhinophyma (bulbous, ruddy nose), telangiectasias, hepatosplenomegaly.
Pain brings these more prominently to medical attention, but painless neuropathies are not uncommon.
Amyloid
Waxy skin, easy bruising, enlarged muscles (tongue and deltoids), cardiac failure or conduction abnormalities, hepatomegaly.
Typically severe neuropathic pain.
Celiac disease Diarrhea, steatorrhea, flatulence, iron deficiency anemia, osteopenia, or osteoporosis.
Variable presentation of symptoms. Causality has not been established.
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Systemic symptoms are primarily related to neurologic involvement (eg, constipation or urinary retention related to autonomic neuropathy).
In small fiber neuropathy associated with large fiber damage, some patients experience pain, but many of these presentations are painless.
Continued on next page Obesity, hypertension, and lipid abnormalities are all common.
Pain is more prominent in the early stages of neuropathy where over 50% of patients with neuropathy develop pain, but a large proportion are completely painless.
Guillain-Barré syndrome
Classic ascending weakness is the norm; small fiber involvement is typically less apparent.
Small fiber neuropathy associated with large fiber damage; pain is more prominent than in CIDP.
Heavy metal toxicity Lead: abdominal pain, constipation, joint and muscle aches, headache, anorexia, anemia.
Lead, mercury, and n-hexane (glue sniffing) often present with paresthesia or are painless.
Mercury: renal dysfunction.
Arsenic poisoning may present with paresthesia, but is more painful at higher doses. Continued on next page A mixed presentation depending on the underlying deficiency or toxicity; some are painless.
HIV = human immunodeficiency virus.
The pain is typically described as spontaneous burning, shooting pain, tingling, or other dysesthesia. 4 Many patients report cutaneous burning with additional paroxysmal shooting pains. There is also evoked pain that is described as increased sensitivity to nonpainful stimuli (allodynia) or increased pain to painful stimuli (hyperalgesia). The distribution of pain will roughly overlap with the anatomic distribution of damaged nerve fibers.
Neurophysiology: Nerve Conduction Study and EMG
By definition, isolated small fiber neuropathies will have little, if any, large fiber involvement. Nerve conduction studies and EMG will not typically reveal any clinically relevant abnormalities. It should be noted that many disorders, such as diabetes mellitus, will have both large and small fiber involvement. Any abnormalities revealed in nerve conduction studies will reflect the damage to large myelinated nerve fibers and will not confirm or deny the presence of small fiber nerve damage.
Skin Biopsy
Skin biopsy has become the pathologic gold standard used for the diagnosis of a small fiber neuropathy. 1 After local anesthesia with lidocaine, a 3 mm punch skin biopsy is taken. Use of lidocaine with epinephrine 1:100,000 diminishes any associated bleeding, and no sutures are required. Although skin biopsies can be obtained from any region, the biopsy site with most widespread normative data includes the distal leg 10 cm above the lateral malleolus. 5 Other biopsy sites typically include the lateral distal thigh, the lateral proximal thigh, and the instep of the foot. Skin biopsies obtained from other regions may not have normative values. However, in neuropathies with focal unilateral involvement, biopsy of the contralateral, unaffected site can serve as a control.
Skin biopsies are stained with the pan-axonal marker protein gene product 9.5. Established counting methods are used to determine the intraepidermal nerve fiber density. Standard guidelines and worldwide normative data are available, and commercial laboratories have brought this technology into the hands of practicing neurologists, endocrinologists, and primary care physicians. 1, 5 Skin biopsies appear to be used by some clinicians to rule in a diagnosis of small fiber neuropathy in some patients and to rule out a diagnosis of small fiber neuropathy in patients with concerns suggestive of neuropathy, but without confirmatory examination findings. 6 In cases where the skin biopsy is normal, a negative result redirects management toward other items on the differential diagnosis. 6 However, it should be noted that the majority of patients with small fiber neuropathy do not require a skin biopsy for diagnosis; the history and examination findings are sufficient for confirmation in many cases.
Quantitation of other nerve fiber subtypes, such as deeper dermal fibers, sudomotor fibers around sweat glands, and pilomotor fibers contained within arrector pilorum muscles have been described in detail. 7, 8 These techniques may provide valuable insight into selective autonomic neuropathies that may not be detected using standard counting of intraepidermal nerve fibers. It should be noted that methods to quantify the dermal and autonomic nerve are not as well established or as widely accepted as the analysis of intraepidermal nerve fiber density. Despite these limitations, the utility of skin biopsies as potential tools for investigation of a variety of neuropathies continues to grow. Case 13-1 highlights the use of h Typical nerve conduction studies and EMG will not detect a small fiber neuropathy.
h Skin biopsy with immunostaining for protein gene product 9.5 provides the pathologic gold standard for diagnosis of a small fiber neuropathy.
Case 13-1
A 55-year-old woman with symptoms of sicca complex and a possible diagnosis of Sjö gren syndrome was referred for severe, diffuse burning pain over her whole body that had been present for 14 months. She had been evaluated by several physicians, who found no evidence of abnormality on examination. She had nerve conduction studies and EMG that were normal; imaging of the brain and spine was also normal. Detailed neurologic examination showed normal strength and reflexes. Large fiber sensation was normal; however, there was evidence of diminished pinprick and thermal sensitivity, but not in a length-dependent fashion, with associated allodynia. Punch skin biopsies taken from the distal leg, distal thigh, and proximal thigh revealed diminished intraepidermal nerve fiber density at all sites. Methotrexate did not ameliorate her symptoms, and she was started on IV immunoglobulin (IVIg) with monthly infusions and mycophenolate, resulting in a 60% reduction in pain and symptom scores. A skin biopsy repeated 1 year later demonstrated increased intraepidermal nerve fiber density; a summary of these results is shown in Figure 13 shown by black circles, with dotted lines defining the lower threshold of the normal value. In all three biopsy sites, the intraepidermal nerve fiber density (IENFD) is below normal. B, Skin biopsy from the distal leg is shown; the nerve fibers (red) do not pierce the dermal-epidermal junction (yellow line). The red scale bar = 100 Hm. C, Results from the skin biopsy taken 1 year later show a significant increase in IENFD at all three biopsy sites shown by black circles, with dotted lines defining the lower threshold of the normal value. D, Skin biopsy taken from the distal leg 1 year later demonstrates an increase in the epidermal nerve fibers (red) that cross the dermal-epidermal junction (yellow line). The red scale bar = 100 Hm.
Continued on page 1404
skin biopsy in the evaluation of a small fiber neuropathy.
Quantitative Sensory Testing
The use of a standardized method to deliver thermal or vibratory stimuli to measure the threshold at which an individual can detect sensation is known as quantitative sensory testing. It is a well-established and well-validated approach to detect evidence of a neuropathy. A variety of instruments can be used, but the more rigorous and laborintensive methods tend to provide the greatest reliability and reproducibility. 9 Quantitative sensory testing has not gained widespread acceptance in clinical practice because of the length of time required for testing and a lack of reimbursement for the testing procedure.
Autonomic Testing
Autonomic testing encompasses an array of assessments that range from a standard battery of sympathetic adrenergic, sympathetic cholinergic, and sudomotor function tests to organspecific tests, such as urodynamics, pupillometry, and gastric emptying studies. In most cases seen by neurologists, tests of autonomic function will include cardiovagal (parasympathetic), sympathetic adrenergic, and sudomotor (sweating) function. Autonomic testing is discussed in more detail in the article ''Autonomic Neuropathies'' by Paola Sandroni, MD, PhD, FAAN, and Valeria Iodice, MD, in this issue of .
Autonomic testing may guide the investigation of a small fiber neuropathy, particularly if autonomic symptoms are present. 10 In a distal small fiber neuropathy, Quantitative Sudomotor Axon Reflex Test (QSART) may be the first detectable abnormality in neurophysiologic testing. 3 QSART utilizes the axon reflex to assess local sudomotor function by detecting a change in sweat production after iontophoresis (the transport of a medication into the skin via a small electrical current) of acetylcholine. Symptoms of distal anhidrosis may be present in an early neuropathy, and are often overlooked by patients who may actually report a compensatory proximal hyperhidrosis. Thermoregulatory sweat testing produces a topographical map of sweat production by raising the core body temperature and using an indicator dye to demonstrate areas of sweat production ( Figure 13-2) . Thermoregulatory sweat testing and QSART are still relatively specialized, and may not be available in many locations.
SMALL FIBER NEUROPATHIES Differential Diagnosis of Small Fiber Neuropathy
Many disorders are associated with the development of a small fiber neuropathy. However, the majority of new cases will be linked to glucose dysmetabolism secondary to diabetes mellitus or prediabetes. In the evaluation of any patient with small fiber neuropathy, it is important to consider testing for fasting blood Comment. This case highlights a common problem in which patients with a small fiber neuropathy that is not length dependent are often misdiagnosed because there is no gradient in loss of pinprick or thermal sensation. If an unaffected site is used for a comparison, it is easier to detect a loss of pain and thermal sensitivity. Asking a patient where the water still feels hot in a shower is a good clue to sensitive locations. The skin biopsy also confirmed the nonYlength-dependent small fiber neuropathy. It should be noted that IVIg is not a standard treatment for idiopathic small fiber neuropathy, but, in this scenario, the IVIg and mycophenolate were used to treat the presumed autoimmune cause of her neuropathy from Sjö gren syndrome.
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glucose and glycosylated hemoglobin (A 1c ). Table 13 -1 reviews the differential diagnosis of a small fiber neuropathy, including the most common causes, the details about systemic findings associated with each disorder, and the presence or absence of neuropathic pain in each scenario. Table 13 -2 reviews the initial and follow-up investigations in the evaluation of small fiber neuropathy.
In the next several sections, a few important types of small fiber neuropathies for which there is controversy, confusion about the diagnosis, or recent updates in the scientific literature will be highlighted.
Treatment-Induced Neuropathy of Diabetes Mellitus
Previously described as insulin neuritis or acute painful diabetic neuropathy, this disorder occurs in individuals with type 1 or type 2 diabetes mellitus with a history of uncontrolled hyperglycemia and an abrupt improvement in glycemic control. 4, 11 Glucose control can occur with the use of insulin, oral hypoglycemic medications, or severe dietary restriction. There is an associated fall in glycosylated hemoglobin (A 1c ) of 2 percentage points or more over a 3-month period of time. More dynamic drops in A 1c are associated with more severe symptoms and more profound neuropathy.
Clinically, individuals present with the abrupt onset of burning and shooting neuropathic pain in a length-dependent fashion (although it can be nonYlengthdependent pain in those with the largest drops in A 1c ) 2 to 6 weeks after improvement in glucose control. 4 There is an associated loss of intraepidermal nerve fibers in the distribution of pain. Autonomic dysfunction is present in the majority of individuals, but may be masked by the severity of the neuropathic pain.
Patients will often have a normal neurologic examination with the exception of hyperalgesia and allodynia in the distribution of pain. 4 Nerve conduction studies are typically normal. Older individuals with type 2 diabetes mellitus may already have a mild underlying neuropathy with absent ankle reflexes and reduced has normal sweat production (seen by the purple color change of alizarin red in the presence of moisture). The patient had surgery on the right knee with evidence of injury to the lateral cutaneous nerve of the calf. B, A patient diagnosed with impaired glucose tolerance has a distal small fiber neuropathy with no sweat production in the feet or distal legs. C, A patient with a drug reaction caused by metronidazole has patchy loss of sweat production and a painful small fiber neuropathy. Continued on next page distal vibratory sensation, but this likely predates the development of treatment-induced neuropathy of diabetes mellitus. Diagnostically, this problem can be recognized by the association with a change in glucose control. Review of daily glucose logs will often identify the specific date that a change in glycemic control occurred, with pain developing 2 to 6 weeks later. Laboratory testing of A 1c levels can confirm the change in glucose levels, but will underestimate the magnitude of the decrease in A 1c unless a full 3 months has passed since the change in glycemic control. Treatment of the neuropathic pain can be very difficult despite polypharmacy, but often does improve spontaneously after 12 to 24 months. 4 Individuals with type 1 diabetes mellitus may also show clinical improvement in autonomic symptoms and function over this period of time; it is unclear if individuals with type 2 diabetes mellitus have the same degree of recovery. 4 An example of treatment-induced neuropathy is described in Case 13-2.
Sodium Channel Mutations
There have been several disorders associated with sodium channel 1.7 (Nav1.7). Inherited erythromelalgia is a disorder of severe pain with associated color changes, typically present in the feet, that is precipitated by warmth and relieved by cooling. A number of publications have directed attention to the association between Nav1.7 mutations and an inherited pattern of erythromelalgia.
12Y15 Although these cases are relatively few in number, they have highlighted the clinical heterogeneity associated with sodium channel mutations and have provided direct support for the use of sodium channel antagonists, such as carbamazepine, in the treatment of these pain disorders.
In 2012, Faber and colleagues reported that 28.6% of individuals from the Netherlands with idiopathic painful small fiber neuropathy expressed a gain-of-function mutation to voltage-gated Nav1.7 of the SCN9A gene. 16 These individuals showed evidence of hyperexcitable dorsal root ganglia and also endorsed evidence of
KEY POINT
h Treatment-induced neuropathy of diabetes mellitus needs to be considered in any patients with diabetes mellitus who have an abrupt increase in neuropathic pain or autonomic dysfunction. 
Acute intermittent porphyria
Measurement of porphobilinogen in urine and erythrocytes.
Celiac disease Anti-gliadin antibodies (serum immunoglobulin A endomysial and tissue transglutaminase antibody).
There is significant debate about causation. Some individuals present without gastrointestinal manifestations; therefore, the utility of gastrointestinal histopathology in an isolated neuropathy is not known.
Hereditary neuropathies
Testing for hereditary sensory and autonomic neuropathies. autonomic dysfunction. 16 Hyperexcitable sodium channels can result in increased influx of calcium into the axon and overwhelm the sodium-calcium exchange, resulting in axonal degeneration. Although preliminary, these data are exciting and may lead to a greater understanding of small fiber neuropathy and more targeted therapies for patients with pain. In a follow-up study, the authors identified patients with painful small fiber neuropathy that had a gain-of-function mutation to Nav1.8 (gene SCN10A). 17 The patients showed a typical loss of immunostaining for distal epidermal nerve fibers by skin biopsy and had a clinical history consistent with idiopathic small fiber neuropathy. These mutations had been suspected based on animal studies, but this is the first publication demonstrating the existence of the Nav1.8 gain-offunction mutation in humans.
Although these mutations are of intense scientific interest, the genetic testing for these abnormalities is not readily available at this time. Therefore, the clinical implications and recommendations for these disorders are still a work in progress. However, during the next few years, it is expected that a number of genetic tests may become available, along with rapidly changing recommendations.
Voltage-Gated Potassium Channel Autoantibodies
In a retrospective review of cases that were diagnosed with neuronal voltagegated potassium channel autoantibodies, KEY POINT h Selective mutations to the sodium channels are an ongoing area of exciting research, and clinical testing for mutations may be available over the next few years.
Case 13-2
A 23-year-old woman with type 1 diabetes mellitus and a long history of poor glucose control was referred for a neurologic consultation by her primary care physician because of a 5-week history of severe neuropathic pain over most of her body. The pain was severe, and had resulted in two visits to the emergency department. She also had experienced two syncopal spells during that time that occurred while standing. A detailed neurologic examination revealed orthostatic hypotension, a resting tachycardia, diffuse allodynia, and hyperalgesia. She had normal strength, normal reflexes, and an otherwise normal physical and neurologic examination. Her nerve conduction studies and EMG were normal. Skin biopsies at three sites on the right leg revealed diffuse reduction in intraepidermal nerve fiber density with morphological abnormalities such as nerve fiber swellings. Further history revealed that, at the urging of her boyfriend, she had started aggressively controlling her glucose 8 weeks earlier; within 3 weeks, she developed her presenting symptoms, which were consistent with treatment-induced neuropathy of diabetes mellitus. It was only after review of her glucose meter that the cause of the neuropathy became clear. She also developed evidence of retinopathy and worsening renal function synchronously with the development of treatment-induced neuropathy of diabetes mellitus. She maintained her glucose control, and over 18 months her symptoms gradually improved but did not return to her baseline level of function.
Comment. This is a classic case of treatment-induced neuropathy of diabetes mellitus, where microvascular damage to the eyes, kidneys, and nerves occur simultaneously after an abrupt improvement in glycemic control. This problem can be especially difficult to detect if recent blood glucose levels are not available or not known by the patient, but is relatively easy to detect if there is a large decrease in glycosylated hemoglobin values compared with a few months earlier.
a group at the Mayo Clinic showed that a significant proportion of patients had neuropathic pain. 18 Although neuronal voltage-gated potassium channel autoantibodies are not classically associated with a small fiber neuropathy, these patients frequently present with reduced sweating and diminished heat-pain sensation in the distribution of pain. 18 It is important to note that the voltagegated potassium channel autoantibodies do not actually bind to potassium channels. They coprecipitate in the binding assay and actually bind to the leucine-rich glioma inactivated protein 1 (LGI1) in the central nervous system and the contactin-associated proteinlike 2 (CASPR2) in the central and peripheral nervous system. 19 The limited data available suggest that most patients with neuropathic pain and/or small fiber neuropathy have autoantibodies against CASPR2 or both CASPR2 and LGI1, but not LGI1 alone. 19 To date, the association between voltage-gated potassium channelYassociated autoantibodies and individuals presenting with symptoms of small fiber neuropathy has not been established; the Mayo study investigated the presence of painful symptoms in patients who were already known to have voltage-gated potassium channel autoantibodies. This is another exciting area of research that is expected to increase understanding of patients with neuropathic pain and may result in novel therapeutic interventions.
Impaired Glucose Tolerance and Metabolic Syndrome
The association between glucose dysregulation, in the form of impaired glucose tolerance or impaired fasting glucose, and small fiber neuropathy has been known for over a decade. 20, 21 However, extensive debates about whether these findings are causative or associated have raged through the literature.
22Y27
It is curious that little debate exists about the role of diabetes mellitus in the development of neuropathy. An individual with a fasting blood glucose of 126 mg/dL and neuropathy has diabetic neuropathy. An individual with a fasting blood glucose of 125 mg/dL and neuropathy has an idiopathic neuropathy associated with impaired fasting glucose. This somewhat arbitrary threshold for diagnosis of diabetes mellitus seems to hold significant sway over the capacity for different clinicians to agree upon a diagnosis.
Nevertheless, a number of interesting findings have been reported recently in patients with predominantly small fiber neuropathy and glucose dysmetabolism. A diagnosis of diabetes mellitus is made with a hemoglobin A 1c greater than or equal to 6.5%, a 2-hour oral glucose challenge of greater than or equal to 200 mg/dL, or a fasting glucose of greater than or equal to 126 mg/dL. Individuals with prediabetes are diagnosed by an A 1c of 5.7% to 6.4%, a 2-hour oral glucose challenge of 140 mg/dL to 199 mg/dL, or a fasting blood glucose of 100 mg/dL to 125 mg/dL. Healthy individuals are below these criteria on all tests.
In the monitoring of trends and determinants in cardiovascular diseases (MONICA)/German cooperative health research in the region of Augsburg (KORA) study, 28% of individuals with diabetes mellitus had neuropathy, 13% of individuals with impaired glucose tolerance had neuropathy, 11.3% with impaired fasting glucose had neuropathy, and 7.4% of controls had neuropathy. 27 These findings suggest an association, but not causation, between prediabetes and neuropathy.
Several studies have now linked metabolic syndrome with both hyperlipidemia and hyperglycemia as independent risk factors for the development KEY POINT h Fasting blood glucose, 2-hour glucose tolerance testing, and glycosylated hemoglobin should be checked in patients presenting with a small fiber neuropathy.
of neuropathy.
28Y30 These findings are of particular interest because patients with prediabetes often present with small fiber neuropathy that may improve with treatment of the underlying disorders. 24, 25 To date, no clear recommended guidelines on treatment of prediabetes and neuropathy have been established. However, the burden of evidence implicating glucose dysmetabolism and hyperlipidemia with multiple long-term complications suggests early interventions are important in preventing the development of diabetes mellitus and a host of other complications.
Small Fiber Neuropathies in Other Disorders
Fibromyalgia. A recent publication demonstrated that small fiber neuropathy was seen in a disproportionately large number of patients with fibromyalgia. 31 The findings suggest association, but not causation. These results have significant implications for the pathophysiologic basis for fibromyalgia, which has been largely written off as a ''wastebasket'' diagnosis with little in the way of pathologic findings to support the diagnosis. If these findings are confirmed in a larger population of patients with fibromyalgia, it may lead to more targeted therapy that may improve long-term outcomes.
Postural orthostatic tachycardia syndrome. A recent study detected evidence of a small fiber neuropathy in a subset of patients diagnosed with postural orthostatic tachycardia syndrome (POTS). 32 Nine of 24 patients with POTS had biopsy-confirmed evidence of a small fiber neuropathy. The findings in this study also demonstrated that patients with neuropathic POTS had very different physiologic responses on autonomic testing than those individuals without evidence of an underlying neuropathy. These findings suggest an autoimmune etiology that could be amenable to intervention in some patients with POTS.
Although neither of these disorders (fibromyalgia or POTS) present with typical symptoms suggestive of a small fiber neuropathy, both situations highlight the role of small nerve fibers in syndromes that have been largely misunderstood.
Sarcoidosis. Pain is common in patients with sarcoidosis. A recent report describes symptoms suggestive of small fiber neuropathy in two-thirds of individuals with sarcoidosis and no other identified causes of neuropathy. 33 Unlike other small fiber neuropathies, sarcoidosis can frequently cause a nonYlength-dependent neuropathy and may present with migratory symptoms of burning, numbness, allodynia, and paresthesia. 34 Symptoms often progress over time.
Treatment
Treatment of the underlying disorders that cause small fiber neuropathy is beyond the scope of this article. However, it is clear that therapies targeting the underlying disease are the only mechanism to modify the natural history of neuropathy. Treatments of any associated neuropathic pain will improve quality of life, but will not alter the natural history of the disease. Readers are referred to a number of recent publications on the treatment of neuropathic pain. 9, 35 CONCLUSION Small fiber nerve damage is seen in a number of different diseases and requires a detailed history and examination to identify any underlying causative disorder. Extensive laboratory testing is not always necessary because the vast majority of cases of small fiber neuropathy are limited to a few diagnoses. A
KEY POINTS
h Cholesterol and triglyceride levels should be checked in patients with a small fiber neuropathy.
h Identifying and treating the underlying disorder is the only method to alter the natural history of a small fiber neuropathy.
stepwise approach to laboratory testing (described in Table 13 -2) is recommended. A diagnosis of small fiber neuropathy is made by a combination of history and examination findings; confirmatory testing (when necessary) can be obtained through skin biopsy analysis of intraepidermal nerve fiber density. Treatment of the underlying disorder is the only method to modify the natural history of the disease. Many, but not all, individuals with small fiber neuropathy will have associated neuropathic pain and will require symptomatic treatment as well.
